

Summit Corporation plc
(‘Summit’ or ‘the Company’)

**SUMMIT TO PRESENT AT WEDBUSH SECURITIES LIFE SCIENCES
CONFERENCE IN THE US**

Oxford, UK, 6 August 2013 – Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy (‘DMD’) and *C. difficile* infection (‘CDI’), announces that it will be presenting at the Wedbush Securities Life Sciences Management Access Conference in New York on Wednesday 14 August at 08:35 EST (13:35 BST).

Mr Glyn Edwards, the Company’s Chief Executive Officer, will provide a corporate overview, highlighting its lead molecules SMT C1100 for the treatment of DMD and SMT 19969 for the treatment of CDI. In addition, Glyn Edwards will participate in the ‘Leaders in DMD and Rare Diseases’ panel discussion to be held on Tuesday 13 August at 11:30 EST.

A copy of the presentation will be available immediately after the event from the Investors Relations section of the Company’s website at www.summitplc.com.

- END -

Notes to Editors

About Summit

Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and *C. difficile* infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter ([@summitplc](https://twitter.com/summitplc)).

For more information, please contact:

Summit

Glyn Edwards / Richard Pye

Tel: +44 (0)1235 443 939

Nomura Code Securities

(Nominated Adviser and Joint broker)

Chris Collins / Jonathan Senior / Giles Balleny

Tel: +44 (0)20 7776 1200

Hybridan LLP

(Joint broker)

Claire Louise Noyce / Deepak Reddy

Tel: +44 (0)207 947 4350

Peckwater PR

(Financial public relations, UK)

Tarquin Edwards

Tel: +44 (0)7879 458 364

tarquin.edwards@peckwaterpr.co.uk

MacDougall Biomedical Communications

(US media contact)

Michelle Avery

Tel: +1 781-235-3060